RxDoctor Payments DataLook up a doctor →

Jason Shatkin, MD

Pulmonary Disease · Paramus, NJNPI 1669529202

Payments from drug & device makers

$282,202in general payments, 2019–2025

Across 1,025 payments — averaging $275.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$125K
  • Jazz Pharmaceuticals Inc.$61K
  • Avadel CNS Pharmaceuticals, LLC$30K
  • Mylan Specialty L.p.$25K
  • Harmony Biosciences LLC$25K
  • Viatris Specialty LLC$5K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$30,32511%
  • Speaking & faculty fees$225,71980%
  • Travel & lodging$9,9274%
  • Food & beverage$15,6386%
  • Education$5830%
  • Entertainment$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK250$125,412
Jazz Pharmaceuticals Inc.143$60,697
Avadel CNS Pharmaceuticals, LLC60$30,440
Mylan Specialty L.p.90$24,896
Harmony Biosciences LLC85$24,883
Viatris Specialty LLC15$5,161
Viiv Healthcare Company2$3,570
Boehringer Ingelheim23$1,588
AstraZeneca(2 entities)41$801
Johnson & Johnson(3 entities)48$532
Amgen(2 entities)26$411
Sanofi24$378
Actelion Pharmaceuticals US, Inc.27$298
Philips North America LLC16$259
Inspire Medical Systems, Inc.9$198
Sanofi-aventis U.S. LLC2$180
United Therapeutics Corporation16$168
Insmed, Inc.10$141
AbbVie10$137
Merck8$119
Boston Scientific7$111
Pfizer7$106
Eisai Inc.6$106
Abbott2$95
ANI Pharmaceuticals, Inc.6$94
Axsome Therapeutics, Inc.6$90
Lilly USA, LLC6$87
Kowa Pharmaceuticals America, Inc.6$83
Inogen, Inc.3$77
Baxter Healthcare4$70
Genentech USA, Inc.5$69
Verona Pharma, Inc.4$63
Octapharma USA, Inc.3$49
Regeneron Healthcare Solutions, Inc.3$49
Mallinckrodt Hospital Products Inc.3$47
Azurity Pharmaceuticals, Inc.3$44
UCB, Inc.3$40
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$36
Sunovion Pharmaceuticals Inc.2$35
Invivyd Inc2$34
Cvrx, Inc.1$31
Biohaven Pharmaceutical Holding Company Ltd.2$30
Radius Health, Inc.2$29
Kiniksa Pharmaceuticals, Ltd.2$29
Gilead2$28
Medtronic1$28
Teva Pharmaceuticals USA, Inc.2$27
Arbor Pharmaceuticals, Inc.2$27
Itamar Medical Inc2$25
Aerin Medical Inc.1$23
Electromed, Inc.2$21
Tonix Medicines, Inc.1$17
Grifols USA, LLC1$16
Idorsia Pharmaceuticals US Inc1$15
E.r. Squibb & Sons, L.L.C.1$15
Celltrion USA Inc.1$15
Paratek Pharmaceuticals, Inc.1$15
Acadia Pharmaceuticals Inc1$15
Circassia Inc.1$14
Xeris Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$282,202 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$608,710
Medicare patients
656
Services billed
9,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate54$1,082,650
Trelegy ElliptaFluticasone/Umeclidin/Vilanter371$416,316
LumryzSodium Oxybate13$245,343
EliquisApixaban29$39,774
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$34,980
Pirfenidone12$34,358
XareltoRivaroxaban28$32,013
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$24,298
Breo ElliptaFluticasone/Vilanterol12$10,536
DayvigoLemborexant11$6,625
Ipratropium Bromide98$4,939
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,515
Modafinil17$3,750
Albuterol Sulfate HfaAlbuterol Sulfate69$3,400
Armodafinil12$2,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$125,412$461,831430 claims
Avadel CNS Pharmaceuticals, LLCLumryz$30,440$245,34313 claims
PfizerEliquis$106$39,77429 claims
Johnson & JohnsonXarelto$532$32,01328 claims
AstraZenecaBreztri Aerosphere$801$24,29824 claims
Eisai Inc.Dayvigo$106$6,62511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →